Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP547 for cholestatic pruritus in primary biliary cholangitis or primary sclerosing cholangitis
2021-002526-25Phase 2Completed
- Sponsor
- Escient Pharmaceuticals
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cholestatic pruritus, primary biliary cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) comparing EP547 with Placebo (2 arms). Primary endpoint: Change from baseline in WI-NRS at Week 6. Started Oct 2022; status: completed.
02
Drugs
EP547
03
Conditions
cholestatic pruritusprimary biliary cholangitis (PBC)Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2021-002526-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002526-25.